Cargando…
A case of Ménétriere´s disease treated with the monoclonal antibody cetuximab
Ménétriere´s disease is a rare disorder of the body and fundus of the stomach, characterized by a massive proliferation of the foveolar cells and subsequent excess mucous secretion. This results in hypoproteinemia due to loss of serum proteins across the gastric mucosa. The cause of Ménétriere´s dis...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885025/ https://www.ncbi.nlm.nih.gov/pubmed/31123980 http://dx.doi.org/10.1007/s12328-019-00994-8 |
_version_ | 1783474669664337920 |
---|---|
author | Carlsen, Arne Grimstad, Tore Bjørn Karlsen, Lars Normann Greve, Ole Jacob Norheim, Katrine Brække Lea, Dordi |
author_facet | Carlsen, Arne Grimstad, Tore Bjørn Karlsen, Lars Normann Greve, Ole Jacob Norheim, Katrine Brække Lea, Dordi |
author_sort | Carlsen, Arne |
collection | PubMed |
description | Ménétriere´s disease is a rare disorder of the body and fundus of the stomach, characterized by a massive proliferation of the foveolar cells and subsequent excess mucous secretion. This results in hypoproteinemia due to loss of serum proteins across the gastric mucosa. The cause of Ménétriere´s disease is unknown, and due to the irreversible and premalignant character of the disorder, the patients affected have been subdued to gastrectomy as the only curable treatment. Epidermial growth factor (EGF) has been implicated in the pathogenesis, a finding that makes the disorder receptive to monoclonal antibody treatment against the EGF receptor. In this case report, we present a 41-year-old woman referred to our emergency department due to dizziness, nausea, and vomiting. A thorough medical investigation, combining clinical history, laboratory investigations, an upper endoscopy with full-thickness snare biopsies, and a CT scan confirmed Ménétriere´s disease, and she was successfully treated with the monoclonal antibody cetuximab. |
format | Online Article Text |
id | pubmed-6885025 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer Japan |
record_format | MEDLINE/PubMed |
spelling | pubmed-68850252019-12-12 A case of Ménétriere´s disease treated with the monoclonal antibody cetuximab Carlsen, Arne Grimstad, Tore Bjørn Karlsen, Lars Normann Greve, Ole Jacob Norheim, Katrine Brække Lea, Dordi Clin J Gastroenterol Case Report Ménétriere´s disease is a rare disorder of the body and fundus of the stomach, characterized by a massive proliferation of the foveolar cells and subsequent excess mucous secretion. This results in hypoproteinemia due to loss of serum proteins across the gastric mucosa. The cause of Ménétriere´s disease is unknown, and due to the irreversible and premalignant character of the disorder, the patients affected have been subdued to gastrectomy as the only curable treatment. Epidermial growth factor (EGF) has been implicated in the pathogenesis, a finding that makes the disorder receptive to monoclonal antibody treatment against the EGF receptor. In this case report, we present a 41-year-old woman referred to our emergency department due to dizziness, nausea, and vomiting. A thorough medical investigation, combining clinical history, laboratory investigations, an upper endoscopy with full-thickness snare biopsies, and a CT scan confirmed Ménétriere´s disease, and she was successfully treated with the monoclonal antibody cetuximab. Springer Japan 2019-05-23 2019 /pmc/articles/PMC6885025/ /pubmed/31123980 http://dx.doi.org/10.1007/s12328-019-00994-8 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Case Report Carlsen, Arne Grimstad, Tore Bjørn Karlsen, Lars Normann Greve, Ole Jacob Norheim, Katrine Brække Lea, Dordi A case of Ménétriere´s disease treated with the monoclonal antibody cetuximab |
title | A case of Ménétriere´s disease treated with the monoclonal antibody cetuximab |
title_full | A case of Ménétriere´s disease treated with the monoclonal antibody cetuximab |
title_fullStr | A case of Ménétriere´s disease treated with the monoclonal antibody cetuximab |
title_full_unstemmed | A case of Ménétriere´s disease treated with the monoclonal antibody cetuximab |
title_short | A case of Ménétriere´s disease treated with the monoclonal antibody cetuximab |
title_sort | case of ménétriere´s disease treated with the monoclonal antibody cetuximab |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885025/ https://www.ncbi.nlm.nih.gov/pubmed/31123980 http://dx.doi.org/10.1007/s12328-019-00994-8 |
work_keys_str_mv | AT carlsenarne acaseofmenetrieresdiseasetreatedwiththemonoclonalantibodycetuximab AT grimstadtorebjørn acaseofmenetrieresdiseasetreatedwiththemonoclonalantibodycetuximab AT karlsenlarsnormann acaseofmenetrieresdiseasetreatedwiththemonoclonalantibodycetuximab AT greveolejacob acaseofmenetrieresdiseasetreatedwiththemonoclonalantibodycetuximab AT norheimkatrinebrække acaseofmenetrieresdiseasetreatedwiththemonoclonalantibodycetuximab AT leadordi acaseofmenetrieresdiseasetreatedwiththemonoclonalantibodycetuximab AT carlsenarne caseofmenetrieresdiseasetreatedwiththemonoclonalantibodycetuximab AT grimstadtorebjørn caseofmenetrieresdiseasetreatedwiththemonoclonalantibodycetuximab AT karlsenlarsnormann caseofmenetrieresdiseasetreatedwiththemonoclonalantibodycetuximab AT greveolejacob caseofmenetrieresdiseasetreatedwiththemonoclonalantibodycetuximab AT norheimkatrinebrække caseofmenetrieresdiseasetreatedwiththemonoclonalantibodycetuximab AT leadordi caseofmenetrieresdiseasetreatedwiththemonoclonalantibodycetuximab |